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• Delta-24-RGD and Delta-24-RGDOX 
show great efficacy infecting and killing 
human and murine breast cancer cells 
in vitro.
• Treatment of murine models with armed 
oncolytic viruses increased T-cell 
specific anti-tumor responses and thus 
controls primary tumor growth and 
metastasis. 
FUTURE INVESTIGATION:
The development of oncolytic viruses has 
introduced a paradigm shift in our 
approach to cancer treatment. Our data 
may constitute the basis for the 
development of virotherapy in patients with 
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In this study, we hypothesize that oncolytic virotherapy will elicit a robust antitumor immune 
response, which will exert abscopal effects and eradicate primary tumors and metastatic 
niches in metastatic breast cancer models.
HYPOTHESISBACKGROUND
Ø Metastatic breast cancer (MBC) is one
of the most lethal cancer types 
worldwide. 
Ø Current therapies include 
chemotherapy, radiotherapy, and 
surgery. However, these methods are 
ineffective with regards to improving long-
term survival rates for patients with MBC.
Ø Delta-24-RGD has shown much success 
infecting and killing cancer cells in
addition to inducing CD4+ T-Cell 
immune response. The response from
the immune system inadvertently initiates 
abscopal effects, as indicated in a phase 1 
clinical trial.
Figure 2. Immunohistochemical 
staining for E1A. Indicative successful 
of viral infection in glioblastoma. 
Adapted from Lang et al., JCO, 2018.
Figure 3. Immunohistochemical staining for Hexon protein. Indicative 
successful of replication of Delta-24-RGD in glioblastoma. Adapted from 
Lang et al., JCO, 2018.
24 BP deletion prevents viral replication 
in normal cells while increasing 
replication in Rb deficient cancer cells
24 BP RGD-4C coding sequence 
improves the infectivity of the virus.
Replacement of E3 Region and 
addition of costimulatory ligand OX40L 
enables proliferation of T-cells.
Figure 1. Genomic structure of Delta-24-RGDOX
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Figure 9. %CD4/CD8 T-Cell response in spleen, 
tumor, and lymph nodes. Tissue samples were 
collected from live mice analyzed with Flow Cytometry.
** Statistically significant. Two-way ANOVA p<0.001
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Figure 5. Viability assay for murine (A) and human (B,C) MBC cell lines in vitro. Cell lines were infected with appropriate MOI of viruses and monitored over a period of 144 hours. 
Cytotoxic effects are measured using Viral ToxGlo™-Promega
Figure 6. Observation of breast cancer metastasis in female BALB/c murine populations. BLI imaging was performed more than 2 weeks after 1st  dose (5 weeks after cell implant).
Figure 7. Tumor volumes in murine 
population (mm3).
Figure 8. Intensity of 4T1 primary breast tumor in 
murine population (p/s). Luciferin expression via BLI.
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Figure 10. Percent lung (A) and brain 
(B) Metastasis in murine population after treatment.
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